IPO GMP Today: Why the Grey Market Is Wrong 4 in 10 Times (2026)

Every IPO site in India leads with the same number. GMP up, apply. GMP down, skip. It is presented with the confidence of a stock price and the precision of a decimal, and almost none of those sites will tell you where the figure comes from or how often it has been wrong. We publish GMP ourselves, so this is not an outsider taking shots — it is the number we get the most questions about and trust the least.

The honest position is narrower than either camp will tell you. GMP is not noise, and it is not a prediction. It is a sentiment reading with a known bias, a known blind spot, and a known failure mode — and the failure mode shows up precisely in the IPOs where retail applicants are most concentrated.

What grey market premium actually is

GMP is the price at which IPO applications and allotted shares change hands informally, before listing, between private parties. There is no exchange, no clearing corporation, no settlement guarantee and no regulator. A small set of dealers — concentrated in a few trading hubs — quote a premium, and aggregator sites report those quotes.

That matters because of who sets it. A regulated price reflects thousands of participants transacting under disclosure rules. A GMP quote reflects a handful of operators who may hold inventory, may have a position in the outcome, and face no obligation to publish anything truthfully. When you read "GMP Rs 45", you are reading one small market's opinion, relayed second-hand.

How often is IPO GMP right?

This has finally been studied properly. A 2026 paper examined 205 mainboard IPOs listed on Indian exchanges between 2020 and 2025, of which 64 carried verifiable pre-listing GMP observations. The overall correlation between GMP and listing-day underpricing is genuinely strong — around 0.913. That single number is what GMP defenders quote, and on its own it is misleading, because the reliability turns out to be highly conditional.

Read that cold-market row again, because it is the whole argument. GMP is at its most accurate when sentiment is strong and nearly everything lists at a gain — the conditions in which you barely need a filter. It degrades in weak markets, where a bad application actually costs you. An indicator that works when the answer is obvious and fails when it is not is not a risk tool.

IPO listing gains in 2026 have been negative

The backdrop matters more than any individual GMP quote. India has had 44 mainboard and SME listings in 2026. Among the 19 mainboard issues, 8 now trade below their issue price and the average listing gain across the set is negative — around -1.3%. That follows 2025, where roughly three of every four new listings flopped on debut.

This is what a cold market looks like — and by the study's own finding, it is the regime in which GMP systematically overstates what you will get. The two facts compound. The period when the most applicants are chasing listing gains on GMP signals is the period when those signals carry their largest positive bias.

Why SME IPO GMP is the least trustworthy of all

The grey market for SME issues is thin. Where a mainboard IPO has enough informal volume to make manipulation expensive, an SME quote can be moved by a small number of interested parties — including people connected to the issue itself. A high SME GMP is sometimes a demand signal and sometimes an advertisement.

SEBI has tightened this segment substantially, and most GMP aggregators do not mention any of it next to the premium they are quoting:

What to watch instead of GMP

None of this means apply blind. It means shifting weight onto numbers that are disclosed, sourced and hard to fake. In rough order of how much they deserve your attention:

The OFS split is the most under-read line in any prospectus. A fresh issue puts money into the business. An offer for sale moves money to existing shareholders who are choosing to reduce their stake at this valuation, at this moment. Both are legitimate. Only one of them tells you the company gets funded — and SEBI capping SME OFS at 20% is a direct acknowledgement of how that structure was being used.

How to use GMP without being used by it

There is a defensible way to read the number. Use it as a tiebreaker after the disclosed data has already made your case, never as the case itself. If QIB subscription is strong, the valuation is defensible against listed peers and the fresh-issue share is meaningful, a positive GMP is mild confirmation. If those three are weak, no premium rescues the application.

Read next

Read next: why the biggest mistake new F&O traders make is sizing, not direction and risk of ruin — why a winning system still goes broke, both of which apply directly to a Rs 2 lakh single-name application. For live issues, the IPO board carries subscription and timeline data for every open and upcoming listing.